Literature DB >> 10068311

Pathologic evaluation of the human suprachiasmatic nucleus in severe dementia.

E G Stopa1, L Volicer, V Kuo-Leblanc, D Harper, D Lathi, B Tate, A Satlin.   

Abstract

Sleep disruption and other circadian rhythm disturbances are frequently seen in dementia patients. In this study, we examined the suprachiasmatic nucleus (SCN), the putative site of the hypothalamic circadian pacemaker, to determine the nature and degree of pathologic changes caused by severe dementia. Neuropathologic examination indicated that among 30 patients with a clinical history of severe dementia, 22 had Braak and Braak stage V-VI Alzheimer disease, 3 had combined Alzheimer and Parkinson disease, 3 had Pick disease and 2 had severe hippocampal sclerosis. Comparisons were made with a control group composed of 13 age-matched patients with no clinical or pathological evidence of dementia or other CNS disorders. To determine the pathologic involvement within the SCN, human hypothalami were stained with: Nissl, Bielchowsky silver, thioflavin S and specific antibodies directed against vasopressin (VP), neurotensin (NT), neuropeptide Y (NPY), vasoactive intestinal peptide (VIP), beta-amyloid (B/A4) and glial fibrillary acidic protein (GFAP). Pathologic damage was primarily limited to neuronal loss and neurofibrillary tangle formation. Only rare diffuse plaques were noted. The pathologic changes within the SCN were less severe than in the other brain regions. Morphometric analysis was accomplished using a stereological approach to sample the average total number of positively stained neurons and astrocytes in 10 different 0.1mm2 microscopic fields in the dorsal subdivision of the SCN. Patients with Alzheimer disease exhibited a significant decrease in vasopressin (9.75 vs 16.7, p < 0.001) and neurotensin (6.82 vs 9.63, p < 0.002) neurons, as well as a corresponding increase in the GFAP-stained astrocyte/Nissl-stained neuron ratio (0.54 vs 0.10, p < 0.009). These studies provide evidence that both vasopressin and neurotensin neurons are lost in Alzheimer disease, and that the astrocyte/neuron ratio is a reliable indicator of disease-related pathology within the SCN. Taken collectively, our data support the hypothesis that damage to the SCN may be an underlying anatomical substrate for the clinically observed changes in circadian rhythmicity that have been observed in Alzheimer patients.

Entities:  

Mesh:

Year:  1999        PMID: 10068311     DOI: 10.1097/00005072-199901000-00004

Source DB:  PubMed          Journal:  J Neuropathol Exp Neurol        ISSN: 0022-3069            Impact factor:   3.685


  65 in total

Review 1.  Melatonin antioxidative defense: therapeutical implications for aging and neurodegenerative processes.

Authors:  Seithikurippu R Pandi-Perumal; Ahmed S BaHammam; Gregory M Brown; D Warren Spence; Vijay K Bharti; Charanjit Kaur; Rüdiger Hardeland; Daniel P Cardinali
Journal:  Neurotox Res       Date:  2012-06-28       Impact factor: 3.911

Review 2.  The role of neurotensin in central nervous system pathophysiology: what is the evidence?

Authors:  Fannie St-Gelais; Claudia Jomphe; Louis-Eric Trudeau
Journal:  J Psychiatry Neurosci       Date:  2006-07       Impact factor: 6.186

Review 3.  The management of sleep and circadian disturbance in patients with dementia.

Authors:  Qiuping Pearl Zhou; Lorena Jung; Kathy C Richards
Journal:  Curr Neurol Neurosci Rep       Date:  2012-04       Impact factor: 5.081

4.  Update on the Diagnosis and Management of Sleep Disturbances in Dementia.

Authors:  Bradley F Boeve
Journal:  Sleep Med Clin       Date:  2008-09

Review 5.  'The clocks that time us'--circadian rhythms in neurodegenerative disorders.

Authors:  Aleksandar Videnovic; Alpar S Lazar; Roger A Barker; Sebastiaan Overeem
Journal:  Nat Rev Neurol       Date:  2014-11-11       Impact factor: 42.937

Review 6.  Use of sleep-promoting medications in nursing home residents : risks versus benefits.

Authors:  David K Conn; Robert Madan
Journal:  Drugs Aging       Date:  2006       Impact factor: 3.923

7.  Severe impairment of circadian rhythm in Alzheimer's disease.

Authors:  L Volicer; D G Harper; E G Stopa
Journal:  J Nutr Health Aging       Date:  2012-10       Impact factor: 4.075

8.  Microtubules modulate melatonin receptors involved in phase-shifting circadian activity rhythms: in vitro and in vivo evidence.

Authors:  Michael J Jarzynka; Deepshikha K Passey; David A Johnson; Nagarjun V Konduru; Nicholas F Fitz; Nicholas M Radio; Mark Rasenick; Susan Benloucif; Melissa A Melan; Paula A Witt-Enderby
Journal:  J Pineal Res       Date:  2008-10-28       Impact factor: 13.007

9.  Behavioral and SCN neurophysiological disruption in the Tg-SwDI mouse model of Alzheimer's disease.

Authors:  Jodi R Paul; Hira A Munir; Thomas van Groen; Karen L Gamble
Journal:  Neurobiol Dis       Date:  2018-03-11       Impact factor: 5.996

Review 10.  Rhythms of life: circadian disruption and brain disorders across the lifespan.

Authors:  Ryan W Logan; Colleen A McClung
Journal:  Nat Rev Neurosci       Date:  2019-01       Impact factor: 34.870

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.